Suppr超能文献

一例SMARCB1(INI1)缺陷型胸内肿瘤病例,该肿瘤对非小细胞肺癌化疗无反应且进展迅速。

A Case of an SMARCB1 (INI1)-Deficient Intrathoracic Neoplasm That Did Not Respond to Chemotherapy for Non-Small Cell Lung Cancer and Rapidly Progressed.

作者信息

Moriyasu Yutaro, Tsuda Takeshi, Matsuyama Kei, Mizushima Isami, Azechi Kenji, Masaki Yasuaki, Abo Hitoshi, Aikawa Akane, Ishizawa Shin, Taniguchi Hirokazu

机构信息

Department of Respiratory Medicine, Toyama Prefectural Central Hospital, Toyama, Japan.

Department of Diagnostic Radiology, Toyama Prefectural Central Hospital, Toyama, Japan.

出版信息

Case Rep Oncol. 2025 Feb 11;18(1):339-345. doi: 10.1159/000544167. eCollection 2025 Jan-Dec.

Abstract

INTRODUCTION

SMARCB1 (INI1)-deficient intrathoracic neoplasms are rare and highly malignant. We report a case of a patient with this tumor who was initially diagnosed with non-small cell lung cancer and whose disease rapidly progressed to death despite chemotherapy.

CASE PRESENTATION

A man in his 60s was diagnosed with a mass exceeding 10 cm in the lower lobe of the right lung and a right pleural effusion on the first examination. Transbronchial biopsy of the primary lesion revealed a tumor with rhabdoid features, which was diagnosed as an undifferentiated malignant neoplasm. Clinically, the patient was diagnosed with non-small cell lung cancer and was treated with carboplatin, nab-paclitaxel, durvalumab, and tremelimumab. However, at the end of the second course, there was rapid disease progression. Based on a pathological review, the tumor was considered an SMARCB1-deficient intrathoracic neoplasm. Although we considered further treatment, his general condition deteriorated, and he died about 2 months after his first visit.

CONCLUSION

This disease is rare, and we believe that it is necessary to disseminate the concept of this disease and accumulate knowledge to establish a treatment.

摘要

引言

SMARCB1(INI1)缺陷型胸内肿瘤罕见且恶性程度高。我们报告一例最初被诊断为非小细胞肺癌的该肿瘤患者,尽管接受了化疗,但其病情仍迅速进展直至死亡。

病例介绍

一名60多岁男性在首次检查时被诊断为右肺下叶有一个超过10厘米的肿块及右侧胸腔积液。对原发灶进行经支气管活检显示肿瘤具有横纹肌样特征,被诊断为未分化恶性肿瘤。临床上,该患者被诊断为非小细胞肺癌,并接受了卡铂、白蛋白结合型紫杉醇、度伐利尤单抗和曲美木单抗治疗。然而,在第二个疗程结束时,病情迅速进展。经病理复查,该肿瘤被认为是SMARCB1缺陷型胸内肿瘤。尽管我们考虑了进一步治疗,但他的一般状况恶化,在首次就诊后约2个月死亡。

结论

这种疾病罕见,我们认为有必要传播该疾病的概念并积累知识以确立治疗方法。

相似文献

4
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
6
The Black Book of Psychotropic Dosing and Monitoring.
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
7
Nivolumab for adults with Hodgkin's lymphoma (a rapid review using the software RobotReviewer).
Cochrane Database Syst Rev. 2018 Jul 12;7(7):CD012556. doi: 10.1002/14651858.CD012556.pub2.
10
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.

本文引用的文献

4
Immunotherapy in SMARCB1 (INI-1)-deficient sinonasal carcinoma: Two case reports.
World J Clin Cases. 2023 Nov 16;11(32):7911-7919. doi: 10.12998/wjcc.v11.i32.7911.
7
Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms.
Mod Pathol. 2022 Dec;35(12):1860-1869. doi: 10.1038/s41379-022-01133-4. Epub 2022 Jul 21.
8
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015.
J Thorac Oncol. 2022 Mar;17(3):362-387. doi: 10.1016/j.jtho.2021.11.003. Epub 2021 Nov 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验